Verastem (VSTM) Projected to Release Earnings on Thursday

Key Points

• Verastem is expected to report Q3 2026 results after the market closes on November 5, with analysts projecting a loss of $0.44 per share and revenue of $26.57 million.
• The company beat estimates in the prior quarter, reporting a $0.35-per-share loss versus the expected $0.43 loss and revenue of $40.08 million, compared with the $22.88 million consensus.
• Analyst sentiment remains generally positive, with 11 Buy, one Hold, and one Sell rating producing a “Moderate Buy” consensus and an average price target of $16.67; shares recently traded at $9.84.

Verastem (NASDAQ:VSTM - Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Verastem to post earnings of ($0.44) per share and revenue of $26.57 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Verastem (NASDAQ:VSTM - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. The firm had revenue of $40.08 million during the quarter, compared to analysts' expectations of $22.88 million. On average, analysts expect Verastem to post ($1.51) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.

Verastem Price Performance

NASDAQ VSTM opened at $9.84 on Thursday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.22 and a current ratio of 2.25. The firm's 50 day moving average price is $8.05 and its 200-day moving average price is $6.16. Verastem has a 52-week low of $3.43 and a 52-week high of $10.82. The company has a market cap of $891.14 million, a PE ratio of -3.70 and a beta of 0.39.

Insider Activity at Verastem

In other news, CEO Dan Paterson sold 44,121 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $8.00, for a total transaction of $352,968.00. Following the completion of the sale, the chief executive officer owned 652,712 shares in the company, valued at approximately $5,221,696. This represents a 6.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 48,044 shares of company stock worth $381,484. Corporate insiders own 1.94% of the company's stock.

Wall Street Analyst Weigh In

VSTM has been the subject of a number of analyst reports. Mizuho upped their target price on Verastem from $13.00 to $14.00 and gave the stock an "outperform" rating in a report on Friday, October 16th. Guggenheim set a $12.00 price target on Verastem and gave the company a "buy" rating in a report on Friday, August 7th. Wall Street Zen upgraded Verastem from a "sell" rating to a "hold" rating in a report on Sunday, September 27th. Alliance Global Partners reissued a "buy" rating on shares of Verastem in a research report on Thursday, October 15th. Finally, Weiss Ratings cut Verastem from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, October 15th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.67.

About Verastem

Verastem, operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company's research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem's leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.